4//SEC Filing
Duvall Diantha 4
Accession 0001457612-21-000042
CIK 0001457612other
Filed
Mar 16, 8:00 PM ET
Accepted
Mar 17, 1:59 PM ET
Size
9.6 KB
Accession
0001457612-21-000042
Insider Transaction Report
Form 4
Duvall Diantha
CHIEF FINANCIAL OFFICER
Transactions
- Award
Common Stock
2021-03-15+37,500→ 37,500 total - Award
Stock Option (Right to Buy)
2021-03-15+112,500→ 112,500 totalExercise: $3.01Exp: 2031-03-15→ Common Stock (112,500 underlying) - Award
Restricted Stock Unit
2021-03-15+100,000→ 100,000 total→ Common Stock (100,000 underlying)
Footnotes (4)
- [F1]Restricted stock units that represent the contingent right to receive, at settlement, one share of common stock. The restricted stock units are scheduled to vest 25% on each of the first four anniversaries of the grant date.
- [F2]The options are scheduled to vest in 48 equal monthly installments beginning on the first monthly anniversary of the grant date.
- [F3]Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- [F4]Vesting of these restricted stock units depends on the average closing price of a share of Genocea Biosciences, Inc.'s common stock over the sixty trading days immediately preceding December 31, 2023. The"target" number of restricted stock units is reported. Between 75% and 150% of the target number of units may vest on December 31, 2023, with the vesting percentage determined based on actual performance.
Documents
Issuer
GENOCEA BIOSCIENCES, INC.
CIK 0001457612
Entity typeother
Related Parties
1- filerCIK 0001696784
Filing Metadata
- Form type
- 4
- Filed
- Mar 16, 8:00 PM ET
- Accepted
- Mar 17, 1:59 PM ET
- Size
- 9.6 KB